Bristol secures £ 45M to advance gene therapy treatment of chronic kidney diseases

The University of Bristol has secured a £ 45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, Research; Faculty of Life Sciences, Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news